Abstract
On October 4—7, 2013 Baltimore (USA) hosted the Annual Congress of the American Society for Bone and Mineral Research (ASMBR), during which many publications were devoted to denosumab, a human monoclonal antibody to the main pathogenic link of osteoporosis — RANK-ligand, which results in a dramatic suppression of bone resorption, creating favorable conditions for the restoration of bone and a marked reduction in fracture risk. Some of the papers presented at the Congress deserve special attention and are discussed in this publication. These studies add new colors to the overall picture of denosumab action, showing efficacy of long-term treatment to suppress bone resorption, increase BMD, reduce fracture risk, improvement in the quality of the cortical bone tissue, ultrastructuralpreservation of normal bone parameters.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
